
Glaukos Corporation
- Jurisdiction
United States - LEI
5299004JA1LHE21M6T14 - ISIN
US3773221029 (GKOS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Read full profile
Fundamentals
- Net revenue
€369.29M - Gross margin
76.3% - EBIT
-€82.47M - EBIT margin
-22.3% - Net income
-€79.15M - Net margin
-21.4%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Ray Dalio |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 1, 2024 (Q1 2024)